U.S. Markets closed

Trinity Biotech plc (TRIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1000-0.0200 (-0.94%)
At close: 4:00PM EDT
2.0300 -0.07 (-3.33%)
After hours: 04:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.1200
Bid2.0600 x 1300
Ask2.1300 x 2200
Day's Range2.0500 - 2.1500
52 Week Range1.7500 - 6.8200
Avg. Volume164,020
Market Cap43.893M
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-0.3060
Earnings DateNov 15, 2021 - Nov 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 05, 2015
1y Target EstN/A

    Sidoti - Fall Virtual Small Cap Investor Conference

    Presentation Times and Weblinks Released for Over 130 Presenting CompaniesWednesday and Thursday, September 22 - 23, 2021NEW YORK, NY / ACCESSWIRE / September 21, 2021 / Sidoti & Company, LLC proudly releases the presentation schedule, with weblink click-throughs, for its Sidoti Fall Virtual Small Cap Investor Conference, to be held on Wednesday, September 22, 2021, and Thursday, September 23, 2021. Virtual Agenda - Wednesday, September 22nd - All Times EDT Click on Company Name to Open Link to

  • Benzinga

    35 Stocks Moving In Thursday's Mid-Day Session

    Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE: OPAD) surged 35.3% to $15.62. Torrid Holdings Inc. (NYSE: CURV) shares gained 26.1% to $23.29 after the company reported better-than-expected Q2 EPS and sales results. Torrid sees Q3 sales of $305 million - $315 million, above the consensus of $294.74 million. The company expects FY21 sales of $1.29 billion - $1.31 billio

  • GlobeNewswire

    Trinity Biotech Announces Results for Q2, 2021

    DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2021. Quarter 2 ResultsTotal revenues for Q2, 2021 were $25.8m, which compares to $16.0m in Q2, 2020, an increase of $9.8m and which were broken down as follows: 2020Quarter 22021Quarter 2 Increase US$’000US$’000%Point-of-Care1,2671,95854.5%